Ocuphire Pharma Inc. (OCUP): Price and Financial Metrics
OCUP Price/Volume Stats
| Current price | $1.53 | 52-week high | $6.60 |
| Prev. close | $1.54 | 52-week low | $1.50 |
| Day low | $1.50 | Volume | 89,800 |
| Day high | $1.56 | Avg. volume | 219,278 |
| 50-day MA | $2.11 | Dividend yield | N/A |
| 200-day MA | $3.03 | Market Cap | 37.96M |
OCUP Stock Price Chart Interactive Chart >
Ocuphire Pharma Inc. (OCUP) Company Bio
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. (from company website @ https://www.ocuphire.com/about)
Latest OCUP News From Around the Web
Below are the latest news stories about OCUPHIRE PHARMA INC that investors may wish to consider to help them evaluate OCUP as an investment opportunity.
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024Often the best investments are out-of-favor and trade at silly cheap valuations. |
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIIIInvestor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023FARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the Company’s CEO, George Magrath M.D., M.B.A., M.S., will deliver a presentation at the Ophthalmology Innovation Summit (OI |
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved an equity award under Ocuphire’s 2021 Inducement Plan, as a material inducement to Joseph K. Schachle, the Company’s newly appointed Chief Oper |
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating OfficerMr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial OperationsFARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of Joseph (Joe) K. Schachle, |
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate UpdateSuccessful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3 Presbyopia Trial Met Primary Endpoint; Viatris Expected to Continue Phase 3 Development in 1H 2024 George Magrath, M.D., M.B.A., M.S. Named as CEO; Conference Call Scheduled for December 5th, 2023, at 10 AM ET FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasd |
OCUP Price Returns
| 1-mo | -24.63% |
| 3-mo | -43.75% |
| 6-mo | -44.57% |
| 1-year | -70.41% |
| 3-year | -69.52% |
| 5-year | N/A |
| YTD | -49.17% |
| 2023 | -14.73% |
| 2022 | -5.36% |
| 2021 | -42.53% |
| 2020 | -15.05% |
| 2019 | N/A |
Loading social stream, please wait...